These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37125735)

  • 1. Comparison of the Correlation Between Coagulation Indices and Rivaroxaban Concentrations.
    Wu T; Wu S; Li M; Zhang J
    Ann Pharmacother; 2024 Jan; 58(1):28-36. PubMed ID: 37125735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of rivaroxaban concentrations demonstrates lack of clinical utility of a PT, dPT and APTT test in estimating levels.
    Thom I; Cameron G; Robertson D; Watson HG
    Int J Lab Hematol; 2018 Aug; 40(4):493-499. PubMed ID: 29718586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
    Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of methods to determine rivaroxaban anti-factor Xa activity.
    Rathbun S; Tafur A; Grant R; Esmon N; Mauer K; Marlar RA
    Thromb Res; 2015 Feb; 135(2):394-7. PubMed ID: 25476589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
    Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
    Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
    Douxfils J; Tamigniau A; Chatelain B; Chatelain C; Wallemacq P; Dogné JM; Mullier F
    Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
    Liu Z; Xie Q; Zhang H; Mu G; Zhou S; Wang Z; Jiang J; Xiang Q; Cui Y
    Am J Cardiovasc Drugs; 2021 Nov; 21(6):669-679. PubMed ID: 34142346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.
    Zhang Y; Qian Q; Qian G; Sun G
    Br J Biomed Sci; 2016 Jul; 73(3):134-139. PubMed ID: 27400196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).
    Derogis PB; Sanches LR; de Aranda VF; Colombini MP; Mangueira CL; Katz M; Faulhaber AC; Mendes CE; Ferreira CE; França CN; Guerra JC
    PLoS One; 2017; 12(2):e0171272. PubMed ID: 28170419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time.
    Bae J; Kim H; Kim W; Kim S; Park J; Jung DI; Yu D
    J Vet Intern Med; 2019 May; 33(3):1322-1330. PubMed ID: 30859645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
    Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
    Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of point-of-care coagulation tests as alternatives to anti-Xa activity for monitoring the anticoagulant effects of rivaroxaban in healthy dogs.
    Lynch AM; Ruterbories LK; Griffith EH; Hanel RM; Stablein AP; Brooks MB
    J Vet Emerg Crit Care (San Antonio); 2021 Jan; 31(1):18-24. PubMed ID: 33118685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
    Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
    J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
    Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
    Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.